Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection

J Infect. 2021 Mar;82(3):414-451. doi: 10.1016/j.jinf.2020.10.005. Epub 2020 Oct 8.

Authors

Jianping Bi¹, Sheng Wang¹, Yajie Wang¹, Dongqin Yang¹, Vivek Verma¹, Jing Huang¹, Guang Han²

Affiliations

¹ Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
² Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China. Electronic address: hg7913@hotmail.com.

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Laboratories
Neoplasms* / complications
Neoplasms* / drug therapy
SARS-CoV-2

Substances

Immune Checkpoint Inhibitors